Teacher Retirement System of Texas raised its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) by 5.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,793 shares of the biotechnology company’s stock after buying an additional 206 shares during the period. Teacher Retirement System of Texas’ holdings in Enanta Pharmaceuticals were worth $270,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. KBC Group NV acquired a new stake in Enanta Pharmaceuticals in the 1st quarter valued at $113,000. Point72 Hong Kong Ltd acquired a new stake in Enanta Pharmaceuticals in the 4th quarter valued at $114,000. Soleus Capital Management L.P. increased its stake in Enanta Pharmaceuticals by 74.5% in the 4th quarter. Soleus Capital Management L.P. now owns 318,275 shares of the biotechnology company’s stock valued at $23,801,000 after buying an additional 135,875 shares during the last quarter. Portland Global Advisors LLC increased its stake in Enanta Pharmaceuticals by 21.1% in the 4th quarter. Portland Global Advisors LLC now owns 75,869 shares of the biotechnology company’s stock valued at $5,673,000 after buying an additional 13,234 shares during the last quarter. Finally, C M Bidwell & Associates Ltd. acquired a new stake in Enanta Pharmaceuticals in the 4th quarter valued at $85,000. 98.87% of the stock is currently owned by institutional investors and hedge funds.
Enanta Pharmaceuticals Stock Performance
Shares of ENTA opened at $61.98 on Friday. Enanta Pharmaceuticals, Inc. has a 52 week low of $37.59 and a 52 week high of $102.00. The firm has a market cap of $1.28 billion, a P/E ratio of -10.58 and a beta of 0.58. The firm’s 50-day simple moving average is $56.17 and its 200 day simple moving average is $58.79.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last announced its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.17). Enanta Pharmaceuticals had a negative net margin of 134.21% and a negative return on equity of 32.42%. The company had revenue of $19.48 million during the quarter, compared to analyst estimates of $20.73 million. During the same quarter last year, the company posted ($1.19) EPS. The firm’s quarterly revenue was down 9.9% on a year-over-year basis. As a group, equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -5.75 earnings per share for the current year.
Analyst Ratings Changes
Several equities research analysts have issued reports on the stock. Robert W. Baird lowered their price target on shares of Enanta Pharmaceuticals from $130.00 to $90.00 and set an “outperform” rating on the stock in a research note on Thursday, May 19th. Roth Capital lowered their price objective on shares of Enanta Pharmaceuticals from $101.00 to $70.00 in a research note on Wednesday, May 11th. Oppenheimer boosted their price objective on shares of Enanta Pharmaceuticals from $53.00 to $59.00 and gave the stock a “market perform” rating in a research note on Wednesday, August 10th. Royal Bank of Canada lowered their price objective on shares of Enanta Pharmaceuticals from $67.00 to $66.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 9th. Finally, JMP Securities boosted their price objective on shares of Enanta Pharmaceuticals from $103.00 to $137.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 9th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.63.
Enanta Pharmaceuticals Profile
(Get Rating)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Further Reading
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating).
Receive News & Ratings for Enanta Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
